diaDexus, Inc. is reiterating its guidance of total revenues in the range of $26 to $28 million for 2014. Product sales revenue of the PLAC ELISA Kit have begun to stabilize following the previously disclosed industry-wide impact from guidance issued to cardiovascular testing facilities in June 2014. Total revenue includes service revenue from the $4.8 million service agreement with GSK, of which $3.6 million was reported in the first nine months of 2014.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
2021 | Diadexus, Inc. Went Out of Business | CI |
2018 | Motion for Asset Sale Approved for Diadexus, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 410 | |
-35.23% | 1.22B | |
-18.38% | 57.21M |
- Stock Market
- Equities
- DDXSQ Stock
- News Diadexus, Inc.
- DiaDexus, Inc. Reiterates Revenue Guidance for the Year 2014